University General Hospital Of Thessaloniki Ahepa
- Address
- lock Available on a paid plan
University General Hospital Of Thessaloniki Ahepa
The University General Hospital of Thessaloniki AHEPA stands as a distinguished center for cardiovascular and neurological research, with extensive expertise in stroke prevention and cardiac care. The institution demonstrates strong capabilities in conducting complex Phase 2 and Phase 3 clinical trials across multiple therapeutic areas, particularly focusing on innovative treatments for acute and chronic cardiovascular conditions.
- Stroke Prevention and Management - including acute ischemic stroke, high-risk transient ischemic attack, and novel anticoagulation therapies
- Cardiovascular Disease - acute coronary syndrome, myocardial infarction, atrial fibrillation, and heart failure with reduced ejection fraction
- Hematologic Malignancies - Hodgkin lymphoma, diffuse large B-cell lymphoma, and acute myeloid leukemia in both pediatric and adult populations
- Ophthalmology and Metabolic Disorders - glaucoma treatments, obesity management, and pulmonary arterial hypertension
The center participates in cutting-edge international trials evaluating novel therapeutic mechanisms including Factor XIa inhibitors for stroke prevention, immunotherapies for lymphoma, and advanced treatments for pulmonary arterial hypertension. With involvement in studies spanning from pediatric oncology to neurodegenerative diseases like multiple sclerosis, and rare conditions such as Ewing sarcoma, AHEPA demonstrates comprehensive research capabilities across diverse patient populations and complex disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 271 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 256 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 52 by active trials.
- 1Novartis Pharma AG7active
lock +51 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S14trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University General Hospital Of Thessaloniki Ahepa
lock Showing 1 of 147 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of Somapacitan and Somatropin in Pediatric Patients with Short Stature Due to SGA, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2022 | — |
IMP list
lock Showing 1 of 271 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 7 | Unknown | 2015-06-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.